Cargando…

Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis

BACKGROUND: The aim of this study was to examine the relative efficacy and safety of boceprevir and telaprevir, when used in combination with pegylated interferon alpha and ribavirin, using an indirect comparison meta-analysis. METHODS: Published phase II and phase III randomized placebo-controlled...

Descripción completa

Detalles Bibliográficos
Autores principales: Cooper, Curtis L, Druyts, Eric, Thorlund, Kristian, Nachega, Jean B, El Khoury, Antoine C, O’Regan, Christopher, Mills, Edward J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3307664/
https://www.ncbi.nlm.nih.gov/pubmed/22442631
http://dx.doi.org/10.2147/TCRM.S29830
_version_ 1782227343422521344
author Cooper, Curtis L
Druyts, Eric
Thorlund, Kristian
Nachega, Jean B
El Khoury, Antoine C
O’Regan, Christopher
Mills, Edward J
author_facet Cooper, Curtis L
Druyts, Eric
Thorlund, Kristian
Nachega, Jean B
El Khoury, Antoine C
O’Regan, Christopher
Mills, Edward J
author_sort Cooper, Curtis L
collection PubMed
description BACKGROUND: The aim of this study was to examine the relative efficacy and safety of boceprevir and telaprevir, when used in combination with pegylated interferon alpha and ribavirin, using an indirect comparison meta-analysis. METHODS: Published phase II and phase III randomized placebo-controlled trials examining the efficacy of boceprevir and telaprevir in chronic hepatitis C virus genotype 1 infected adult populations were included. The primary outcomes were sustained virologic response, relapse, and discontinuation of all study drugs. Secondary outcomes included the adverse events of anemia, neutropenia, rash, and pruritus. RESULTS: Four boceprevir trials and six telaprevir trials were included. No significant differences were observed for sustained virologic response among either naïve (relative risk [RR] 1.14, 95% confidence interval [CI] 0.93–1.37, P = 0.20) or experienced patients (RR 0.81, 95% CI 0.52–1.23, P = 0.30). Similarly, for relapse among naïve (RR 0.80, 95% CI 0.18–3.45, P = 0.77) and experienced patients (RR 1.71, 95% CI 0.90–3.24, P = 0.10), or discontinuation of therapy for naïve (RR 0.80, 95% CI 0.28–2.29, P = 0.72) and experienced patients (RR 0.88, 95% CI 0.69–1.12, P = 0.30). Telaprevir was more likely to be associated with rash and pruritus, and boceprevir was more likely to be associated with neutropenia in certain patient populations. CONCLUSION: Boceprevir and telaprevir appear comparable in terms of sustained virologic response, relapse, or discontinuation of therapy for patients treated with standard-dose therapy durations and response-guided therapy durations.
format Online
Article
Text
id pubmed-3307664
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-33076642012-03-22 Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis Cooper, Curtis L Druyts, Eric Thorlund, Kristian Nachega, Jean B El Khoury, Antoine C O’Regan, Christopher Mills, Edward J Ther Clin Risk Manag Original Research BACKGROUND: The aim of this study was to examine the relative efficacy and safety of boceprevir and telaprevir, when used in combination with pegylated interferon alpha and ribavirin, using an indirect comparison meta-analysis. METHODS: Published phase II and phase III randomized placebo-controlled trials examining the efficacy of boceprevir and telaprevir in chronic hepatitis C virus genotype 1 infected adult populations were included. The primary outcomes were sustained virologic response, relapse, and discontinuation of all study drugs. Secondary outcomes included the adverse events of anemia, neutropenia, rash, and pruritus. RESULTS: Four boceprevir trials and six telaprevir trials were included. No significant differences were observed for sustained virologic response among either naïve (relative risk [RR] 1.14, 95% confidence interval [CI] 0.93–1.37, P = 0.20) or experienced patients (RR 0.81, 95% CI 0.52–1.23, P = 0.30). Similarly, for relapse among naïve (RR 0.80, 95% CI 0.18–3.45, P = 0.77) and experienced patients (RR 1.71, 95% CI 0.90–3.24, P = 0.10), or discontinuation of therapy for naïve (RR 0.80, 95% CI 0.28–2.29, P = 0.72) and experienced patients (RR 0.88, 95% CI 0.69–1.12, P = 0.30). Telaprevir was more likely to be associated with rash and pruritus, and boceprevir was more likely to be associated with neutropenia in certain patient populations. CONCLUSION: Boceprevir and telaprevir appear comparable in terms of sustained virologic response, relapse, or discontinuation of therapy for patients treated with standard-dose therapy durations and response-guided therapy durations. Dove Medical Press 2012 2012-03-09 /pmc/articles/PMC3307664/ /pubmed/22442631 http://dx.doi.org/10.2147/TCRM.S29830 Text en © 2012 Cooper et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Cooper, Curtis L
Druyts, Eric
Thorlund, Kristian
Nachega, Jean B
El Khoury, Antoine C
O’Regan, Christopher
Mills, Edward J
Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis
title Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis
title_full Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis
title_fullStr Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis
title_full_unstemmed Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis
title_short Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis
title_sort boceprevir and telaprevir for the treatment of chronic hepatitis c genotype 1 infection: an indirect comparison meta-analysis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3307664/
https://www.ncbi.nlm.nih.gov/pubmed/22442631
http://dx.doi.org/10.2147/TCRM.S29830
work_keys_str_mv AT coopercurtisl boceprevirandtelaprevirforthetreatmentofchronichepatitiscgenotype1infectionanindirectcomparisonmetaanalysis
AT druytseric boceprevirandtelaprevirforthetreatmentofchronichepatitiscgenotype1infectionanindirectcomparisonmetaanalysis
AT thorlundkristian boceprevirandtelaprevirforthetreatmentofchronichepatitiscgenotype1infectionanindirectcomparisonmetaanalysis
AT nachegajeanb boceprevirandtelaprevirforthetreatmentofchronichepatitiscgenotype1infectionanindirectcomparisonmetaanalysis
AT elkhouryantoinec boceprevirandtelaprevirforthetreatmentofchronichepatitiscgenotype1infectionanindirectcomparisonmetaanalysis
AT oreganchristopher boceprevirandtelaprevirforthetreatmentofchronichepatitiscgenotype1infectionanindirectcomparisonmetaanalysis
AT millsedwardj boceprevirandtelaprevirforthetreatmentofchronichepatitiscgenotype1infectionanindirectcomparisonmetaanalysis